HRP20121010T1 - Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin - Google Patents

Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin Download PDF

Info

Publication number
HRP20121010T1
HRP20121010T1 HRP20121010TT HRP20121010T HRP20121010T1 HR P20121010 T1 HRP20121010 T1 HR P20121010T1 HR P20121010T T HRP20121010T T HR P20121010TT HR P20121010 T HRP20121010 T HR P20121010T HR P20121010 T1 HRP20121010 T1 HR P20121010T1
Authority
HR
Croatia
Prior art keywords
compound
salt
formula
dimethylpiperazine
image
Prior art date
Application number
HRP20121010TT
Other languages
English (en)
Croatian (hr)
Inventor
Benny Bang-Andersen
Klaus Peter Bogeso
Klaus Gjervig Jensen
Henrik Svane
Allan Carsten Dahl
Mark Howells
Lars Ole Lyngso
Tomas Mow
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34199055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20121010(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20121010T1 publication Critical patent/HRP20121010T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
    • C07C35/32—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.3.0) system, e.g. indenols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20121010TT 2003-08-18 2004-08-18 Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin HRP20121010T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49605803P 2003-08-18 2003-08-18
DKPA200301180 2003-08-18
DKPA200301305 2003-09-11
US52024603P 2003-11-14 2003-11-14
PCT/DK2004/000546 WO2005016901A1 (en) 2003-08-18 2004-08-18 Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (1)

Publication Number Publication Date
HRP20121010T1 true HRP20121010T1 (hr) 2013-01-31

Family

ID=34199055

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20121010TT HRP20121010T1 (hr) 2003-08-18 2004-08-18 Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin
HRP20120389TT HRP20120389T1 (hr) 2003-08-18 2004-08-18 Soli sukcinata i malonata trans-4-(ir,3s)-6-klor-3-fenilindan-1-il)-1,2,2-trimetilpiperazina i uporaba kao lijek

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120389TT HRP20120389T1 (hr) 2003-08-18 2004-08-18 Soli sukcinata i malonata trans-4-(ir,3s)-6-klor-3-fenilindan-1-il)-1,2,2-trimetilpiperazina i uporaba kao lijek

Country Status (15)

Country Link
US (4) US7767683B2 (enExample)
EP (2) EP1658276B1 (enExample)
JP (3) JP5144930B2 (enExample)
AU (3) AU2004265022A1 (enExample)
BR (2) BRPI0413595B8 (enExample)
CA (2) CA2536144C (enExample)
CY (1) CY1113039T1 (enExample)
HR (2) HRP20121010T1 (enExample)
IL (2) IL173589A0 (enExample)
IS (1) IS2848B (enExample)
MX (2) MXPA06001938A (enExample)
NO (2) NO20061153L (enExample)
NZ (2) NZ544715A (enExample)
PL (1) PL1658277T3 (enExample)
WO (2) WO2005016901A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP1658276B1 (en) 2003-08-18 2012-10-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
MX2007009816A (es) * 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
PL2020996T3 (pl) * 2006-05-16 2012-04-30 Gilead Sciences Inc Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego
TW200819426A (en) * 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
US7632963B2 (en) 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
SI2125786T1 (sl) * 2006-12-21 2011-05-31 Pfizer Prod Inc Sukcinat sol 2-((4-(1-metil-4-(piridin-4-il)-1H-pirazol-3-il)fenoksi)metil)kinolina
US20090306092A1 (en) * 2008-05-07 2009-12-10 H. Lundbeck A/S Method for treating cognitive deficits
HRP20120700T1 (hr) 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
US20110178094A1 (en) * 2008-10-03 2011-07-21 H. Lundbeck A/S Oral Formulation
TW201102370A (en) * 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
WO2012063843A1 (ja) 2010-11-09 2012-05-18 株式会社カネカ ハロゲン化インデノン類及びそれを用いた光学活性インダノン類又は光学活性インダノール類の製造方法
CN103429577A (zh) * 2011-01-07 2013-12-04 H.隆德贝克有限公司 4-((1r,3s)-6-氯-3-苯基-茚满-1-基)-1,2,2-三甲基哌嗪和1-((1r,3s)-6-氯-3-苯基-茚满-1-基)-3,3-二甲基哌嗪的拆分方法
PE20150928A1 (es) * 2011-06-20 2015-06-26 Lundbeck & Co As H 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
IN2015MN00002A (enExample) 2012-07-09 2015-10-16 Lupin Ltd
CN110054693A (zh) 2012-08-21 2019-07-26 詹森药业有限公司 喹硫平半抗原的抗体及其用途
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
CN104755093B (zh) 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
PT2888234T (pt) 2012-08-21 2018-02-22 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
PT2888592T (pt) 2012-08-21 2018-01-29 Janssen Pharmaceutica Nv Anticorpos contra a quetiapina e sua utilização
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
HK1211956A1 (en) * 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
WO2019193134A1 (en) 2018-04-06 2019-10-10 H. Lundbeck A/S Process for the preparation of 2,2-dimethylpiperazine
US20210395208A1 (en) 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
US11358934B2 (en) * 2020-03-23 2022-06-14 Caamtech, Inc. Crystalline forms of psilacetin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
NZ196284A (en) * 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
DE3837710A1 (de) * 1988-11-07 1990-05-10 Statomat Globe Maschf Verfahren und vorrichtung zum ausrichten der abgemantelten enden von rundkabeln
BR9206722A (pt) 1991-11-05 1995-07-18 Smithkline Beecham Corp Antagonista receptores de endotelina
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja) * 1992-12-22 1994-07-05 Kotobuki Seiyaku Kk ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
JP2686366B2 (ja) 1993-11-30 1997-12-08 ファイザー・インコーポレーテッド キラルテトラロンの製造方法
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en) * 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
PT1073618E (pt) * 1998-05-01 2004-03-31 Pfizer Prod Inc Processo para a producao de sertralina-tetralona enantiomericamente pura ou opticamente enriquecida usando cromotografia continua
ES2258331T3 (es) 1998-05-22 2006-08-16 Scios Inc. Compuestos heterociclicos y procedimientos de tratamiento de insuficiencia cardiaca y otros trastornos.
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
JP2000351773A (ja) * 1999-06-08 2000-12-19 Yamanouchi Pharmaceut Co Ltd フラン誘導体からなる医薬
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (enExample) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
EP1658276B1 (en) * 2003-08-18 2012-10-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
MX2007009816A (es) 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法

Also Published As

Publication number Publication date
JP2011201924A (ja) 2011-10-13
US8076342B2 (en) 2011-12-13
WO2005016900A1 (en) 2005-02-24
HRP20120389T1 (hr) 2012-06-30
EP1658276B1 (en) 2012-10-10
BRPI0413595B8 (pt) 2021-05-25
NO20061151L (no) 2006-03-10
US20060281759A1 (en) 2006-12-14
IS8265A (is) 2006-01-26
JP5553802B2 (ja) 2014-07-16
BRPI0413595A (pt) 2006-10-17
EP1658277A1 (en) 2006-05-24
CA2536144C (en) 2010-09-14
US20060281758A1 (en) 2006-12-14
US8227607B2 (en) 2012-07-24
US20100324291A1 (en) 2010-12-23
CA2536073A1 (en) 2005-02-24
AU2010206058B2 (en) 2012-05-17
MXPA06001938A (es) 2006-05-17
AU2004265021A1 (en) 2005-02-24
CA2536144A1 (en) 2005-02-24
BRPI0413555A (pt) 2006-10-17
IL173788A (en) 2013-01-31
MXPA06001838A (es) 2006-05-04
JP2007502784A (ja) 2007-02-15
AU2010206058C1 (en) 2012-10-25
BRPI0413595B1 (pt) 2018-12-11
US7772240B2 (en) 2010-08-10
IL173589A0 (en) 2006-07-05
AU2004265021A2 (en) 2008-06-26
AU2010206058A1 (en) 2010-08-19
JP2007502783A (ja) 2007-02-15
EP1658276A1 (en) 2006-05-24
NZ544715A (en) 2009-09-25
US20110053957A1 (en) 2011-03-03
NZ575575A (en) 2010-04-30
US7767683B2 (en) 2010-08-03
PL1658277T3 (pl) 2012-10-31
AU2004265022A1 (en) 2005-02-24
AU2004265021B2 (en) 2010-05-27
NO20061153L (no) 2006-03-10
IS2848B (is) 2013-09-15
JP5144930B2 (ja) 2013-02-13
IL173788A0 (en) 2006-07-05
CY1113039T1 (el) 2016-04-13
NO332048B1 (no) 2012-06-11
WO2005016901A1 (en) 2005-02-24
JP5043429B2 (ja) 2012-10-10
EP1658277B1 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
HRP20121010T1 (hr) Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin
CN1882587B (zh) 三环化合物作为甘氨酸转运抑制剂的用途
JP2001515516A (ja) 血管損傷剤としてのコルヒノール誘導体の使用
KR100393133B1 (ko) 레보부피바카인및그의유사체의제조에사용하는라세미화및비대칭변환방법
HRP20100121T1 (hr) Derivati n-(aminoheteroaril)-1h-indol-2-karboksamida, njihovo dobivanje i terapijska primjena
JP6130071B2 (ja) １，７−ナフチリジン誘導体
HU184966B (en) Process for producing phenyl-piperazine derivatives of anti-agression activity
WO2001076599B1 (en) Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form
TW202345829A (zh) 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
CN113336735B (zh) 一种尿石素类化合物、制备方法、药物组合物及用途
EP0280269A1 (de) 3-Amino-dihydro-[1]-benzopyrane und Benzothiopyrane
DD249480A5 (de) 3-amino-dihydro-(1)-benzopyrane und benzothiopyrane
US4568695A (en) 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
WO1999016431A1 (en) Mixtures of enantiomers of aminocyclohexylamides to produce simultaneous analgesia with local anaesthesia or antiarrhythmia
WO2013114173A1 (en) A novel process for the preparation of sitagliptin
JP2008509113A5 (enExample)
EP0473550A1 (de) Indolonaphthyridine
JP5095070B2 (ja) Ｒ−（−）−１−［２−（７−クロロベンゾ［ｂ］チオフェン−３−イル−メトキシ）−２−（２，４−ジクロロフェニル）−エチル］−１Ｈ−イミダゾール
HU189745B (en) Process for producing benzamido-derivatives
HRP20110645T1 (hr) Kristalična baza trans-1-((1r,3s)-6-kloro-3-fenilindan-1-il)-3,3-dimetilpiperazina
CN111166745A (zh) 含消旋氧吡格雷或其盐的组合物及应用
RU2001130147A (ru) Пиридотиенодиазепины, способ их получения и содержащие их фармацевтические композиции
JP2002527515A (ja) 精神障害の処置のための３−テトラヒドロピリジン−４−イルインドール類
TW201249784A (en) Compound, method for producing the same, and method for producing oseltamivir phosphate
CN111150731A (zh) 含氧吡格雷光学异构体或其盐的组合物及应用